Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.11 USD
+1.80 (4.25%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $44.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RARE 44.11 +1.80(4.25%)
Will RARE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Other News for RARE
3 Best Stocks to Buy Now, 4/17/2024, According to Top AnalystsÂ
As more rare disease therapies launch, their prices are rising
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)
Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Ultragenyx Pharmaceutical (RARE)
Crude Oil Down 1%; Charles Schwab Sales Top Estimates